- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01359436
e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Epidermal growth factor receptor (EGFR) plays an important role in the development of non-small cell lung cancer (NSCLC). High EGFR mutation rate is found in certain population, including female, non-smoker, East Asian, and adenocarcinoma. Previous studies have shown that patients of NSCLC with mutant EGFR would have better survival, which was related to EGFR tyrosine kinase inhibitor treatment.1-2 IPASS study has shown that longer progression-free survival (PFS) under gefitinib treatment than that under carboplatin-paclitaxel, in patients with lung adenocarcinoma and clinical characteristics suggesting high EGFR mutation rate.3 However, only some EGFR mutations are associated with sensitivity to tyrosine kinase inhibitor treatment, especially deletion in exon 19 and L858R mutation in exon 21.4-5 Two recent phase III randomized clinical trials evaluated gefitinib treatment and chemotherapy in patients of advanced NSCLC with sensitive EGFR mutaions.6-7 In patients with advanced NSCLC and sensitive EGFR mutations, PFS under gefitinib was 9.2~10.8 months, longer than that under platinum-based chemotherapy. Therefore, to develop individualized treatment for patients with NSCLC, it is important to have EGFR mutation status at the time of diagnosis. Current techniques available for detection of EGFR mutation need direct sequencing of EGFR tyrosine kinase domains, which are costly and time-consuming. 8 For detection for specific EGFR mutations, mutation-specific monoclonal antibodies were developed to detect E746-A750 deletion in exon 19 and L858R in exon 21. In the pilot study, the immunohistochemistry (IHC) assay using mutation-specific antibodies showed a sensitivity of 92% and a specificity of 99%.9 Recent two studies examining the performance of the mutation-specific antibodies disclosed inconsistent sensitivity and specificity. In the study by Akhiko Kawahara et al, IHC assay of NSCLC tumor specimens with anti-delE746-A750 antibody showed a sensitivity of 79%, which was 83% by IHC assay with anti-L858R antibody.10 In the other study by Atsuko Kitamura et al, IHC assay with anti-delE746-A750 antibody showed high specificity but low sensitivity (99% and 40%, respectively). IHC assay with anti-L858R antibody also showed high specificity but low sensitivity (97% and 36%, respectively). The overall sensitivity and specificity of these two mutation-specific antibodies were 96% and 47%.11 The discrepancy between these two studies was currently unknown. Another study conducted in Memorial Sloan-Kettering Cancer Center showed the performance of these two mutation-specific antibodies would be affected by the cutoff of IHC score.12 For anti-L858R antibody, the sensitivity was 76%-95% and the positive predicted value was 99%-100%. For anti-delE746-A750 antibody, the sensitivity was 85%-67% and the positive predicted value was 99%-100%. It is unknown if the performance of these mutation-specific monoclonal antibodies could be enhanced with the use of automated quantitative system (AQUA). However, such techinique needs equipment and further cost, and couldn't offer immediate information about EGFR mutation to clinicians.
Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation specific anti-EGFR and its antigen (EGFR with E746-A750 deletion or L858R mutation) present in the specimens of patients with lung cancer. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific mutant EGFR) in the test specimens. From assessment of the electric signature of semiconductive mutation-specific anti-EGFR antibodies, the eABprobe could offer sensitive detection and precise quantification of specific mutant EGFR.
To develop a real-time diagnostic technique with e- Ab sensor for specific EGFR mutation detection in clinical specimens of NSCLC patients, we conduct a prospective clinical study. In comparison with results from direct sequencing of EGFR, we evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction (such as detection of EGFR mutations other than L858R and DelL746-A750). The potential factors which may interfere with the results would be investigated. With such technique, we can obtain EGFR mutation information of NSCLC patients in cost-saving and time-saving way and can offer more individualized treatment for our patients.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Taipei, Taïwan, 100
- Recrutement
- National Taiwan University Hospital
-
Contact:
- Pan-Chyr Yang, PhD
- Numéro de téléphone: 886-2-2356-2905
- E-mail: pcyang@ntu.edu.tw
-
Chercheur principal:
- Pan-Chyr Yang, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Inclusion: Patients will be enrolled if they fulfill all of the following criteria
With indication for the following interventions:
Thoracentesis Fine-needle aspiration and biopsy of primary tumor or metastases Bronchoalveolar lavage
- With enough residual specimens for further study (Patients would be excluded if they have only limited amount of clinical specimens, which should all be sent for clinical analysis.)
- Consent is obtained from the patient
Exclusion Criteria:
- Patients will be excluded if they couldn't sign the consent. Otherwise, no specific exclusion criteria were considered.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Système de sondage d'anticorps par électrodétection (e-Ab sensing)
|
Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC.
The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats.
In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The performance of e- Ab sensor
Délai: 1 day
|
In comparison with results from direct sequencing of EGFR, we evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction (such as detection of EGFR mutations other than L858R and DelL746-A750)
|
1 day
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Pan-Chyr Yang, PhD, National Taiwan University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs pulmonaires
- Carcinome pulmonaire non à petites cellules
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Anticorps
Autres numéros d'identification d'étude
- 201007059R
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .